FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014144616> ?p ?o ?g. }

• W2014144616 endingPage "2616" @default.
• W2014144616 startingPage "2603" @default.
• W2014144616 abstract "Changes in cannabinoid receptor expression and concentration of endocannabinoids have been described in Parkinson's disease; however, it remains unclear whether they contribute to, or result from, the disease process. To evaluate whether targeting the endocannabinoid system could provide potential benefits in the treatment of the disease, the effect of a monoacylglycerol lipase inhibitor that prevents degradation of 2-arachidonyl-glycerol was tested in mice treated chronically with probenecid and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTPp). Chronic administration of the compound, JZL184 (8 mg/kg), prevented MPTPp-induced motor impairment and preserved the nigrostriatal pathway. Furthermore, none of the hypokinetic effects associated with cannabinoid receptor agonism were observed. In the striatum and substantia nigra pars compacta, MPTPp animals treated with JZL184 exhibited astroglial and microglial phenotypic changes that were accompanied by increases in TGFβ messenger RNA expression and in glial cell-derived neurotrophic factor messenger RNA and protein levels. JZL184 induced an increase in β-catenin translocation to the nucleus, implicating the Wnt/catenin pathway. Together, these results demonstrate a potent neuroprotective effect of JZL184 on the nigrostriatal pathway of parkinsonian animals, likely involving restorative astroglia and microglia activation and the release of neuroprotective and antiinflammatory molecules." @default.
• W2014144616 created "2016-06-24" @default.
• W2014144616 creator A5007292367 @default.
• W2014144616 creator A5009961267 @default.
• W2014144616 creator A5016946894 @default.
• W2014144616 creator A5034461668 @default.
• W2014144616 creator A5043879414 @default.
• W2014144616 creator A5050933998 @default.
• W2014144616 creator A5052262509 @default.
• W2014144616 creator A5058978596 @default.
• W2014144616 creator A5069782045 @default.
• W2014144616 creator A5081476843 @default.
• W2014144616 date "2014-11-01" @default.
• W2014144616 modified "2023-10-17" @default.
• W2014144616 title "The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model" @default.
• W2014144616 cites W1505937405 @default.
• W2014144616 cites W1513230591 @default.
• W2014144616 cites W1542528083 @default.
• W2014144616 cites W1568165441 @default.
• W2014144616 cites W1965712628 @default.
• W2014144616 cites W1970310765 @default.
• W2014144616 cites W1971200109 @default.
• W2014144616 cites W1971258758 @default.
• W2014144616 cites W1978677134 @default.
• W2014144616 cites W1983712244 @default.
• W2014144616 cites W1987096289 @default.
• W2014144616 cites W1992618202 @default.
• W2014144616 cites W1993409952 @default.
• W2014144616 cites W1996001296 @default.
• W2014144616 cites W2010395737 @default.
• W2014144616 cites W2011852660 @default.
• W2014144616 cites W2014877781 @default.
• W2014144616 cites W2015629481 @default.
• W2014144616 cites W2016165381 @default.
• W2014144616 cites W2020978550 @default.
• W2014144616 cites W2022834361 @default.
• W2014144616 cites W2024639041 @default.
• W2014144616 cites W2024653583 @default.
• W2014144616 cites W2028336519 @default.
• W2014144616 cites W2029228061 @default.
• W2014144616 cites W2029471635 @default.
• W2014144616 cites W2030536065 @default.
• W2014144616 cites W2032715817 @default.
• W2014144616 cites W2035382111 @default.
• W2014144616 cites W2038443115 @default.
• W2014144616 cites W2038487696 @default.
• W2014144616 cites W2040558323 @default.
• W2014144616 cites W2041366408 @default.
• W2014144616 cites W2046945092 @default.
• W2014144616 cites W2049542629 @default.
• W2014144616 cites W2051554315 @default.
• W2014144616 cites W2053554709 @default.
• W2014144616 cites W2054722901 @default.
• W2014144616 cites W2054810445 @default.
• W2014144616 cites W2056359268 @default.
• W2014144616 cites W2056413400 @default.
• W2014144616 cites W2058594344 @default.
• W2014144616 cites W2062118842 @default.
• W2014144616 cites W2064046464 @default.
• W2014144616 cites W2065730117 @default.
• W2014144616 cites W2066160656 @default.
• W2014144616 cites W2067705214 @default.
• W2014144616 cites W2071013415 @default.
• W2014144616 cites W2077648124 @default.
• W2014144616 cites W2078852065 @default.
• W2014144616 cites W2083025616 @default.
• W2014144616 cites W2090873558 @default.
• W2014144616 cites W2098025305 @default.
• W2014144616 cites W2098382378 @default.
• W2014144616 cites W2103899142 @default.
• W2014144616 cites W2108435419 @default.
• W2014144616 cites W2110514788 @default.
• W2014144616 cites W2120412340 @default.
• W2014144616 cites W2124248227 @default.
• W2014144616 cites W2126766019 @default.
• W2014144616 cites W2133702956 @default.
• W2014144616 cites W2145731644 @default.
• W2014144616 cites W2150349809 @default.
• W2014144616 cites W2151413914 @default.
• W2014144616 cites W2155801131 @default.
• W2014144616 cites W2162947781 @default.
• W2014144616 cites W2163150813 @default.
• W2014144616 cites W2163269741 @default.
• W2014144616 cites W2171494808 @default.
• W2014144616 cites W4247729308 @default.
• W2014144616 cites W4376848266 @default.
• W2014144616 doi "https://doi.org/10.1016/j.neurobiolaging.2014.05.021" @default.
• W2014144616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24973119" @default.
• W2014144616 hasPublicationYear "2014" @default.
• W2014144616 type Work @default.
• W2014144616 sameAs 2014144616 @default.
• W2014144616 citedByCount "69" @default.
• W2014144616 countsByYear W20141446162015 @default.
• W2014144616 countsByYear W20141446162016 @default.
• W2014144616 countsByYear W20141446162017 @default.
• W2014144616 countsByYear W20141446162018 @default.
• W2014144616 countsByYear W20141446162019 @default.
• W2014144616 countsByYear W20141446162020 @default.

• next